Invitae Corporation (NVTA)
| Previous Close | 0.6700 |
| Open | 0.6624 |
| Bid | 0.6680 x 3100 |
| Ask | 0.6695 x 900 |
| Day's Range | 0.6324 - 0.6801 |
| 52 Week Range | 0.6324 - 3.7750 |
| Volume | |
| Avg. Volume | 9,844,434 |
| Market Cap | 183.934M |
| Beta (5Y Monthly) | 1.70 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -2.7200 |
| Earnings Date | Nov 06, 2023 - Nov 10, 2023 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 1.84 |
- Investing.com
Invitae aims to regain NYSE compliance after average share price falls below $1
San Francisco-based medical genetics company, Invitae (NYSE:NVTA), received a notice from the New York Stock Exchange (NYSE) on Tuesday, indicating that the firm is not in compliance with Section 802.01C of the NYSE Listed Company Manual. The violation was due to the average closing price of Invitae's common stock falling below $1.00 per share over a consecutive 30 trading-day period.
Motley FoolInvitae Stock Analysis: Buy, Sell, or Hold?
Fool.com contributor Parkev Tatevosian considers Invitae (NYSE: NVTA) stock and its financial prospects to determine if investors should buy the stock. *Stock prices used were the afternoon prices of Sept.
- Investing.com
Novavax and Invitae implement cost-cutting measures amid financial challenges
In the volatile world of stock trading, healthcare companies Novavax (NASDAQ:NVAX) and Invitae (NYSE:NVTA) have been making headlines as they navigate significant financial challenges. Both firms are taking measures to reduce costs, aiming to improve their financial standing and appeal to a broader range of investors.
